No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma

byAstrid BradshawandAlisha Yi

December 26, 2024

in StudyGraphics

Reading Time: 1 min read

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

FDA grants priority review for iberdomide-based myeloma regimen

2 Minute Medicine Rewind

Pre-maintenance positron emission tomography/computed tomography and bone marrow multiparameter flow cytometry are important for prognostication in multiple myeloma treated with daratumumab

Heated mittens not found to improve physical hand function in patients with osteoarthritis

RelatedReports

Variation noted across pre- and post-marketing studies for FDA approved devices

Hematology

FDA grants priority review for iberdomide-based myeloma regimen

March 6, 2026

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Weekly Rewinds

2 Minute Medicine Rewind

January 13, 2026

Shorter overall survival among patients with monoclonal gammopathy of undetermined significance

Chronic Disease

Pre-maintenance positron emission tomography/computed tomography and bone marrow multiparameter flow cytometry are important for prognostication in multiple myeloma treated with daratumumab

January 13, 2026

The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Shoulder scalpel, shark scare, Alzheimer dosing tweak, and a Blenrep blow

July 22, 2025

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

Adalimumab may be associated with improved outcomes in the management of pediatric Crohn's disease

Transcranial direct current stimulation affect neural connectivity and subsequent fibromyalgia symptoms

Dacomitinib may be effective in EGFR-associated lung cancer

AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited-stage small cell lung cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports